NXC-201 CAR-T Therapy: Business overview

NXC-201 is a pioneering CAR-T therapy developed by Immix Biopharma, specifically targeting AL amyloidosis and select immune-mediated diseases. This innovative treatment aims to provide rapid and transformative outcomes for patients who have limited options with traditional therapies.